Faculty
Oncology Division
Alphabetical list (active faculty):   
Nancy L. Bartlett

Nancy L. Bartlett, MD

Koman Professor of Medical Oncology


Professor

Department of Medicine

Oncology Division

Medical Oncology

Research Interests

  • Non-Hodgkin's lymphoma
  • Hodgkin's disease
  • Chronic lymphocytic leukemia

Contact

  • 314-362-5654 (office)
  • 314-747-5123 (fax)
  • Division of Oncology
    Mail Stop 8056-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid-Campus Center (office)

Peer-reviewed Manuscripts

  • Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience
    Bennani NN, Tun AM, Carson KR, Geiger JL, Maeda LS, Savage KJ, Rose J, Pinter-Brown L, Lunning MA, Abramson JS, Bartlett NL, Vose JM, Evens AM, Smith SM, Horwitz SM, Ansell SM, Advani RH
    Clin Lymphoma Myeloma Leuk 2021 Oct 16; [Epub ahead of print]
  • NCCN Guidelines(R) Insights: B-Cell Lymphomas, Version 5.2021
    Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H
    J Natl Compr Canc Netw 2021 Nov;19(11):1218-1230
  • Phase I/Dose Expansion Trial of Brentuximab Vedotin/Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ward J, Berrien-Elliott MM, Gomez F, Luo J, Becker-Hapak M, Cashen AF, Wagner-Johnston ND, Maddocks K, Mosior M, Foster M, Krysiak K, Schmidt A, Skidmore ZL, Desai S, Watkins MP, Fischer A, Griffith M, Griffith OL, Fehniger TA, Bartlett NL
    Blood 2021 Nov 15; [Epub ahead of print]
  • Venetoclax With Dose-Adjusted EPOCH-R as Initial Therapy for Patients With Aggressive B-Cell Lymphoma: A Single-Arm, Multicentre, Phase 1 Study
    Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, Maddocks K, Ali-Shaw T, Senese S, Yuan Y, Westin J, Leonard JP
    Lancet Haematol 2021 Nov;8(11):e818-e827
  • Comparison of 2-Year Outcomes With CAR T Cells (ZUMA-1) Vs Salvage Chemotherapy in Refractory Large B-Cell Lymphoma
    Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste E, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C
    Blood Adv 2021 Oct 26;5(20):4149-4155
  • Survival After Autologous Versus Allogeneic Transplantation in Patients With Relapsed and Refractory Hodgkin Lymphoma
    Fakhri B, Yilmaz E, Gao F, Ambinder RF, Jones R, Bartlett NL, Cashen A, Wagner-Johnston N
    Leuk Lymphoma 2021 Oct;62(10):2408-2415
  • Adverse Event Burden in Older Patients With CLL Receiving Bendamustine Plus Rituximab or Ibrutinib Regimens: Alliance A041202
    Ruppert AS, Booth AM, Ding W, Bartlett NL, Brander DM, Coutre S, Brown JR, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma CS, Abramson JS, Little RF, Smith SE, Stone RM, Byrd JC, Mandrekar SJ, Woyach JA
    Leukemia 2021 Oct;35(10):2854-2861
  • Multicenter Analysis of Geriatric Fitness and Real-World Outcomes in Older Patients With Classical Hodgkin Lymphoma
    Orellana-Noia VM, Isaac K, Malecek MK, Bartlett NL, Voorhees TJ, Grover NS, Hwang SR, Bennani NN, Hu R, Hill BT, Mou E, Advani RH, Carter J, David KA, Ballard HJ, Svoboda J, Churnetski MC, Magarelli G, Feldman TA, Cohen JB, Evens AM, Portell CA
    Blood Adv 2021 Sep 28;5(18):3623-3632
  • Optimizing Second-Line Therapy for Hodgkin Lymphoma: A Work in Progress
    Bartlett NL
    J Clin Oncol 2021 Oct 1;39(28):3097-3103
  • CD3xCD20 Bispecific T-Cell Redirectors for Relapsed or Refractory B-Cell Lymphoma
    Ghobadi A, Bartlett NL
    Lancet 2021 Sep 25;398(10306):1109-1110
  • Brentuximab Vedotin in Combination With Nivolumab in Relapsed or Refractory Hodgkin Lymphoma: 3-Year Study Results
    Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF
    Blood 2021 Aug 12;138(6):427-438
  • Phase 1 Study of Oral Azacitidine (CC-486) Plus R-CHOP in Previously Untreated Intermediate- To High-Risk DLBCL
    Martin P, Bartlett NL, Chavez JC, Reagan JL, Smith SM, LaCasce AS, Jones JA, Drew J, Wu C, Mulvey E, Revuelta MV, Cerchietti L, Leonard JP
    Blood 2021 Aug 24; [Epub ahead of print]
  • Prophylactic Corticosteroid Use in Patients Receiving Axicabtagene Ciloleucel for Large B-Cell Lymphoma
    Oluwole OO, Bouabdallah K, Munoz J, De Guibert S, Vose JM, Bartlett NL, Lin Y, Deol A, McSweeney PA, Goy AH, Kersten MJ, Jacobson CA, Farooq U, Minnema MC, Thieblemont C, Timmerman JM, Stiff P, Avivi I, Tzachanis D, Kim JJ, Bashir Z, McLeroy J, Zheng Y, Rossi JM, Johnson L, Goyal L, van Meerten T
    Br J Haematol 2021 Aug;194(4):690-700
  • Brentuximab Vedotin With Chemotherapy for Stage III or IV Classical Hodgkin Lymphoma (ECHELON-1): 5-Year Update of an International, Open-Label, Randomised, Phase 3 Trial
    Straus DJ, Dlugosz-Danecka M, Connors JM, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R, Ansell SM, Younes A, Gallamini A, Liu R, Little M, Fenton K, Fanale M, Radford J
    Lancet Haematol 2021 Jun;8(6):e410-e421
  • Phase I Trial of N-803, an IL15 Receptor Agonist, With Rituximab in Patients With Indolent Non-Hodgkin Lymphoma
    Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA
    Clin Cancer Res 2021 Jun 15;27(12):3339-3350
  • Protect Our Children: Hodgkin Lymphoma Survivors
    Bartlett NL
    Blood 2021 Mar 18;137(11):1433-1434
  • Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-Based Biological Therapy
    Sohani AR, Maurer MJ, Giri S, Pitcher B, Chadburn A, Said JW, Bartlett NL, Czuczman MS, Martin P, Rosenbaum CA, Jung SH, Leonard JP, Cheson BD, Hsi ED
    Am J Surg Pathol 2021 Mar 1;45(3):384-393
  • CAR-T Therapy in Solid Organ Transplant Recipients With Treatment Refractory Posttransplant Lymphoproliferative Disorder
    Krishnamoorthy S, Ghobadi A, Santos RD, Schilling JD, Malone AF, Murad H, Bartlett NL, Alhamad T
    Am J Transplant 2021 Feb;21(2):809-814
  • A Forgotten Friend: CCNU as Palliative Monotherapy in Relapsed Hodgkin Lymphoma
    Russler-Germain DA, Watkins MP, Bartlett NL
    Leuk Lymphoma 2021 Feb;62(2):486-488
  • Polatuzumab Vedotin for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Malecek MK, Watkins MP, Bartlett NL
    Expert Opin Biol Ther 2021 Jul;21(7):831-839
  • Approaches to Aggressive B-Cell Lymphomas in Less Fit Patients
    Bartlett NL
    Hematology Am Soc Hematol Educ Program 2020 Dec 4;2020(1):140-147
  • Brentuximab Vedotin Plus Nivolumab as First-Line Therapy in Older or Chemotherapy-Ineligible Patients With Hodgkin Lymphoma (ACCRU): A Multicentre, Single-Arm, Phase 2 Trial
    Cheson BD, Bartlett NL, LaPlant B, Lee HJ, Advani RJ, Christian B, Diefenbach CS, Feldman TA, Ansell SM
    Lancet Haematol 2020 Nov;7(11):e808-e815
  • A Pilot Study of Lenalidomide Maintenance Therapy After Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma
    Shea L, Watkins MP, Wan F, Cashen AF, Wagner-Johnston ND, Jacoby MA, Abboud CN, DiPersio JF, Hurd DD, Jaglowski SM, Bartlett NL, Fehniger TA
    Biol Blood Marrow Transplant 2020 Dec;26(12):2223-2228
  • Final 5-Year Findings From the Phase 3 HELIOS Study of Ibrutinib Plus Bendamustine and Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Fraser GAM, Chanan-Khan A, Demirkan F, Santucci Silva R, Grosicki S, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Loscertales J, Avigdor A, Rule S, Samoilova O, Pavlovsky MA, Goy A, Mato A, Hallek M, Salman M, Tamegnon M, Sun S, Connor A, Nottage K, Schuier N, Balasubramanian S, Howes A, Cramer P
    Leuk Lymphoma 2020 Dec;61(13):3188-3197
  • A Phase 1b Study of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
    Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, Armand P, Devata S, Izquierdo AR, Lossos IS, Reeder C, Sher T, Chen R, Schwarz SE, Alland L, Strassz A, Prier K, Choe-Juliak C, Ansell SM
    Blood 2020 Nov 19;136(21):2401-2409
  • Hodgkin Lymphoma
    Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL
    Nat Rev Dis Primers 2020 Jul 23;6(1):61
  • Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001
    Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD 3rd, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Miller TP, Friedberg JW
    J Clin Oncol 2020 Sep 10;38(26):3003-3011
  • CAR-Modified Memory-Like NK Cells Exhibit Potent Responses to NK-Resistant Lymphomas
    Gang M, Marin ND, Wong P, Neal CC, Marsala L, Foster M, Schappe T, Meng W, Tran J, Schaettler M, Davila M, Gao F, Cashen AF, Bartlett NL, Mehta-Shah N, Kahl BS, Kim MY, Cooper ML, DiPersio JF, Berrien-Elliott MM, Fehniger TA
    Blood 2020 Nov 12;136(20):2308-2318
  • Longitudinal Toxicity Over Time (ToxT) Analysis to Evaluate Tolerability: A Case Study of Lenalidomide in the CALGB 50401 (Alliance) Trial
    Thanarajasingam G, Leonard JP, Witzig TE, Habermann TM, Blum KA, Bartlett NL, Flowers CR, Pitcher BN, Jung SH, Atherton PJ, Tan A, Novotny PJ, Dueck AC
    Lancet Haematol 2020 Jun;7(6):e490-e497
  • Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma
    Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, Bierman PJ, Jagadeesh D, Mitsuyasu RT, Peace D, Watson PR, Hanna WT, Melani C, Lucas AN, Steinberg SM, Pittaluga S, Jaffe ES, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Fanale MA, Noy A, Wilson WH
    J Clin Oncol 2020 Aug 1;38(22):2519-2529
  • Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Analysis of SWOG S0816
    Ha CS, LeBlanc M, Schoder H, Pinnix CC, Bartlett NL, Evens AM, Hsi ED, Rimsza L, Knopp MV, Zhang J, Leonard JP, Kahl BS, Li H, Smith S, Constine LS, Friedberg JW
    Leuk Lymphoma 2020 Oct;61(10):2442-2447
  • Diffuse Telangiectatic Rash Associated With Novel Antibody Drug Conjugate Therapies
    Sorensen EP, Thrush J, Bartlett NL, Rosman IS, Anadkat MJ, Jones HA
    JAMA Dermatol 2020 May 1;156(5):601-603
  • Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results From the CALGB 50303 Clinical Trial
    Schoder H, Polley MC, Knopp MV, Hall N, Kostakoglu L, Zhang J, Higley HR, Kelloff G, Liu H, Zelenetz AD, Cheson BD, Wagner-Johnston N, Kahl BS, Friedberg JW, Hsi ED, Leonard JP, Schwartz LH, Wilson WH, Bartlett NL
    Blood 2020 Jun 18;135(25):2224-2234
  • The Justification of Vincristine Dose Capping: Tradition, Tradition...tradition!
    Bartlett NL
    Leuk Lymphoma 2020 May;61(5):1007-1009
  • Outcomes of Older Patients in ZUMA-1, a Pivotal Study of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma
    Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, Bartlett NL, Braunschweig I, Jiang Y, Kim JJ, Zheng L, Rossi JM, Locke FL
    Blood 2020 Jun 4;135(23):2106-2109
  • Bortezomib Consolidation or Maintenance Following Immunochemotherapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: CALGB/Alliance 50403
    Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N, Pettinger A, Byrd JC, Blum KA, LaCasce AS, Hsi ED, Liu YT, Scott DW, Hurd D, Ruppert AS, Hernandez-Ilizaliturri F, Leonard JP, Cheson BD
    Am J Hematol 2020 Jun;95(6):583-593
  • First-In-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination With Rituximab in Patients With Follicular and Other CD20(+) Non-Hodgkin Lymphomas
    Gopal AK, Levy R, Houot R, Patel SP, Popplewell L, Jacobson C, Mu XJ, Deng S, Ching KA, Chen Y, Davis CB, Huang B, Fly KD, Thall A, Woolfson A, Bartlett NL
    Clin Cancer Res 2020 Jun 1;26(11):2524-2534
  • Rituximab/Bendamustine and Rituximab/Cytarabine Induction Therapy for Transplant-Eligible Mantle Cell Lymphoma
    Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E
    Blood Adv 2020 Mar 10;4(5):858-867
  • Brentuximab Vedotin With Chemotherapy for Stage III/IV Classical Hodgkin Lymphoma: 3-Year Update of the ECHELON-1 Study
    Straus DJ, Dlugosz-Danecka M, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero-Torres A, Gallamini A
    Blood 2020 Mar 5;135(10):735-742
  • Treatment of Nodular Lymphocyte Hodgkin Lymphoma: The Goldilocks Principle
    Bartlett NL
    J Clin Oncol 2020 Mar 1;38(7):662-668
  • Five-Year Follow-Up of SWOG S0816: Limitations and Values of a PET-Adapted Approach With Stage III/IV Hodgkin Lymphoma
    Stephens DM, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg JW
    Blood 2019 Oct 10;134(15):1238-1246
  • Randomized Trial of Ofatumumab and Bendamustine Versus Ofatumumab, Bendamustine, and Bortezomib in Previously Untreated Patients With High-Risk Follicular Lymphoma: CALGB 50904 (Alliance)
    Blum KA, Polley MY, Jung SH, Dockter TJ, Anderson S, Hsi ED, Wagner-Johnston N, Christian B, Atkins J, Cheson BD, Leonard JP, Bartlett NL
    Cancer 2019 Oct 1;125(19):3378-3389
  • Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-Cell Lymphoma: A Single Institution Experience
    Patel DA, Johanns TM, Trinkaus K, Bartlett NL, Wagner-Johnston N, Cashen AF
    Clin Lymphoma Myeloma Leuk 2019 Dec;19(12):806-811
  • Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome
    Fakhri B, Cashen AF, Duncavage EJ, Watkins MP, Wartman LD, Bartlett NL
    Clin Lymphoma Myeloma Leuk 2019 Sep;19(9):e532-e535
  • Apparent Appendicitis in Amyand Hernia With Unexpected Pathology
    Russler-Germain DA, Fraum TJ, Watkins MP, Bartlett NL
    Int J Case Rep Images 2019;10:101030Z01DG2019
  • Polatuzumab Vedotin in Combination With Immunochemotherapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma: An Open-Label, Non-Randomised, Phase 1b-2 Study
    Tilly H, Morschhauser F, Bartlett NL, Mehta A, Salles G, Haioun C, Munoz J, Chen AI, Kolibaba K, Lu D, Yan M, Penuel E, Hirata J, Lee C, Sharman JP
    Lancet Oncol 2019 Jul;20(7):998-1010
  • Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial
    Lavezzi SM, de Jong J, Neyens M, Cramer P, Demirkan F, Fraser G, Bartlett N, Dilhuydy MS, Loscertales J, Avigdor A, Rule S, Samoilova O, Goy A, Ganguly S, Salman M, Howes A, Mahler M, De Nicolao G, Poggesi I
    Pharm Res 2019 May 1;36(7):93
  • Chemotherapy-Induced First Bite Syndrome: A Case Report in a Patient With Hodgkin Lymphoma
    Valenzuela CV, Bartlett NL, Bradley JP
    Ear Nose Throat J 2019 Jun;98(5):E30-E31
  • Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
    Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schoder H, Zelenetz AD, Leonard JP
    J Clin Oncol 2019 Jul 20;37(21):1790-1799
  • Progressive Multifocal Leukoencephalopathy Treated With Nivolumab
    Hoang E, Bartlett NL, Goyal MS, Schmidt RE, Clifford DB
    J Neurovirol 2019 Apr;25(2):284-287
  • Parameters for Validating a Hospital Pneumatic Tube System
    Farnsworth CW, Webber DM, Krekeler JA, Budelier MM, Bartlett NL, Gronowski AM
    Clin Chem 2019 May;65(5):694-702
  • To the Editor, a Multicenter, Open-Label, Early Access Treatment Protocol for Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Martin P, Goy A, Ramchandren R, Ferrante L, Londhe A, McGowan T, Bartlett NL
    J Oncol Pharm Pract 2019 Jun;25(4):1027-1030
  • Phase 2 Multicentre Study of Single-Agent Ofatumumab in Previously Untreated Follicular Lymphoma: CALGB 50901 (Alliance)
    Rosenbaum CA, Jung SH, Pitcher B, Bartlett NL, Smith SM, Hsi E, Wagner-Johnston N, Thomas SP, Leonard JP, Cheson BD
    Br J Haematol 2019 Apr;185(1):53-64
  • Serum Levels of TARC, MDC, IL-10, and Soluble CD163 in Hodgkin Lymphoma: A SWOG S0816 Correlative Study
    Hsi ED, Li H, Nixon AB, Schoder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW
    Blood 2019 Apr 18;133(16):1762-1765
  • A Phase 1 Trial of Ibrutinib Plus Palbociclib in Previously Treated Mantle Cell Lymphoma
    Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, Ridling L, Dittus C, Chen Z, Huang X, Inghirami G, DiLiberto M, Chen-Kiang S, Leonard JP
    Blood 2019 Mar 14;133(11):1201-1204
  • Brentuximab Vedotin Plus Chemotherapy in North American Subjects With Newly Diagnosed Stage III or IV Hodgkin Lymphoma
    Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ
    Clin Cancer Res 2019 Mar 15;25(6):1718-1726
  • The Prognostic Significance of PFS24 in Follicular Lymphoma Following Firstline Immunotherapy: A Combined Analysis of 3 CALGB Trials
    Lansigan F, Barak I, Pitcher B, Jung SH, Cheson BD, Czuczman M, Martin P, Hsi E, Schoder H, Smith S, Bartlett NL, Leonard JP, Blum KA
    Cancer Med 2019 Jan;8(1):165-173
  • Brentuximab Vedotin With Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma (ECHELON-2): A Global, Double-Blind, Randomised, Phase 3 Trial
    Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illes A, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Huttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trumper L
    ECHELON-2 Study Group

    Lancet 2019 Jan 19;393(10168):229-240
  • Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1-2 Trial
    Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS
    Lancet Oncol 2019 Jan;20(1):31-42
  • Updated Results From the Phase 3 HELIOS Study of Ibrutinib, Bendamustine, and Rituximab in Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Pavlovsky MA, Karlsson C, Hallek M, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Chanan-Khan A
    Leukemia 2019 Apr;33(4):969-980
  • ABVD Plus Rituximab Versus ABVD Alone for Advanced Stage, High-Risk Classical Hodgkin Lymphoma: A Randomized Phase 2 Study
    Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ
    Haematologica 2019 Feb;104(2):e65-e67
  • Formulating a Treatment Plan in Suspected Lymphoma: Ultrasound-Guided Core Needle Biopsy Versus Core Needle Biopsy and Fine-Needle Aspiration of Peripheral Lymph Nodes
    Drylewicz MR, Watkins MP, Shetty AS, Lin MF, Salter A, Bartlett NL, Middleton WD, Yano M
    J Ultrasound Med 2019 Mar;38(3):581-586
  • Dose-Adjusted EPOCH-R (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab) in Untreated Aggressive Diffuse Large B-Cell Lymphoma With MYC Rearrangement: A Prospective, Multicentre, Single-Arm Phase 2 Study
    Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH
    Lancet Haematol 2018 Dec;5(12):e609-e617
  • Ibrutinib Regimens Versus Chemoimmunotherapy in Older Patients With Untreated CLL
    Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC
    N Engl J Med 2018 Dec 27;379(26):2517-2528
  • CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
    Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM
    N Engl J Med 2018 Nov 1;379(18):1711-1721
  • Rituximab Plus Lenalidomide in Advanced Untreated Follicular Lymphoma
    Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, Lopez-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, Andre M, Zachee P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA
    RELEVANCE Trial Investigators

    N Engl J Med 2018 Sep 6;379(10):934-947
  • Chimeric Antigen Receptor T-Cell Therapy
    Ogba N, Arwood NM, Bartlett NL, Bloom M, Brown P, Brown C, Budde EL, Carlson R, Farnia S, Fry TJ, Garber M, Gardner RA, Gurschick L, Kropf P, Reitan JJ, Sauter C, Shah B, Shpall EJ, Rosen ST
    J Natl Compr Canc Netw 2018 Sep;16(9):1092-1106
  • In Situ Vaccination With a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma
    Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Long SR, Hoppe RT, Janssen R, Candia AF, Coffman RL, Levy R
    Cancer Discov 2018 Oct;8(10):1258-1269
  • CALGB 50604: Risk-Adapted Treatment of Nonbulky Early-Stage Hodgkin Lymphoma Based on Interim PET
    Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schoder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL
    Blood 2018 Sep 6;132(10):1013-1021
  • Sustained Efficacy and Detailed Clinical Follow-Up of First-Line Ibrutinib Treatment in Older Patients With Chronic Lymphocytic Leukemia: Extended Phase 3 Results From RESONATE-2
    Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P
    Haematologica 2018 Sep;103(9):1502-1510
  • Frequency and Impact of Grade Three or Four Toxicities of Novel Agents on Outcomes of Older Patients With Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma (Alliance A151611)
    Tallarico M, Foster JC, Seisler D, Lafky JM, Hurria A, Jatoi A, Cohen HJ, Muss HB, Bartlett N, Cheson BD, Jung SH, Leonard JP, Byrd JC, Nabhan C
    J Geriatr Oncol 2018 Jul;9(4):321-328
  • Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
    Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM
    N Engl J Med 2018 Apr 12;378(15):1396-1407
  • Five-Year Outcomes for Frontline Brentuximab Vedotin With CHP for CD30-Expressing Peripheral T-Cell Lymphomas
    Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Uttarwar M, Lee SY, Ren H, Kennedy DA, Shustov AR
    Blood 2018 May 10;131(19):2120-2124
  • Management of Relapsed/Refractory Classical Hodgkin Lymphoma in Transplant-Ineligible Patients
    Mehta-Shah N, Bartlett NL
    Blood 2018 Apr 12;131(15):1698-1703
  • Impact of Histological Grading on Survival in the SWOG S0016 Follicular Lymphoma Cohort
    Rimsza LM, Li H, Braziel RM, Spier CM, Persky DO, Dunlap J, LeBlanc M, Bartlett N, Leonard JP, Smith SM, Press OW, Friedberg JW
    Haematologica 2018 Apr;103(4):e151-e153
  • Interim Results of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
    Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH
    Blood 2018 Mar 15;131(11):1183-1194
  • Brentuximab Vedotin With Chemotherapy for Stage III or IV Hodgkin's Lymphoma
    Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J
    ECHELON-1 Study Group

    N Engl J Med 2018 Jan 25;378(4):331-344
  • Single-Agent Ibrutinib in Relapsed or Refractory Follicular Lymphoma: A Phase 2 Consortium Trial
    Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, Thye LS, Anderson DM, Krysiak K, Ramirez C, Qi J, Siegel BA, Griffith M, Griffith OL, Gomez F, Fehniger TA
    Blood 2018 Jan 11;131(2):182-190
  • Outcomes in Adolescents and Young Adults With Hodgkin Lymphoma Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis
    Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM
    Cancer 2018 Jan 1;124(1):136-144
  • Minimal Activity of Nanoparticle Albumin-Bound (Nab) Paclitaxel in Relapsed or Refractory Lymphomas: Results of a Phase-I Study
    Goyal S, Oak E, Luo J, Cashen AF, Carson K, Fehniger T, DiPersio J, Bartlett NL, Wagner-Johnston ND
    Leuk Lymphoma 2018 Feb;59(2):357-362
  • Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
    Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY
    N Engl J Med 2017 Dec 28;377(26):2531-2544
  • Emerging Role of Novel Therapies in Hodgkin Lymphoma: Proceed With Caution
    Bartlett NL
    Hematology Am Soc Hematol Educ Program 2017 Dec 8;2017(1):317-323
  • A Phase II Trial of Lenalidomide Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL): CALGB 50803 (Alliance)
    Martin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, Hsi ED, Ruan J, Smith SE, Leonard JP, Cheson BD
    Ann Oncol 2017 Nov 1;28(11):2806-2812
  • Outcomes of Adults and Children With Primary Mediastinal B-Cell Lymphoma Treated With Dose-Adjusted EPOCH-R
    Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP
    Br J Haematol 2017 Dec;179(5):739-747
  • Five-Year Results of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
    Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A
    Blood 2017 Dec 21;130(25):2709-2717
  • Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
    Lee YS, Liu J, Fricano KA, Webb EM, Toolsie DR, Jones S, Rhoads JA, Vij R, Cashen AF, Abboud CN, Westervelt P, Bartlett NL, DiPersio JF, Kreisel FH, Lim KH
    Biol Blood Marrow Transplant 2017 Dec;23(12):2199-2204
  • A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma
    Maly JJ, Christian BA, Zhu X, Wei L, Sexton JL, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston ND, Phelps MA, Bartlett NL, Blum KA
    Clin Lymphoma Myeloma Leuk 2017 Jun;17(6):347-353
  • Long-Term Outcomes, Secondary Malignancies and Stem Cell Collection Following Bendamustine in Patients With Previously Treated Non-Hodgkin Lymphoma
    Martin P, Chen Z, Cheson BD, Robinson KS, Williams M, Rajguru SA, Friedberg JW, van der Jagt RH, LaCasce AS, Joyce R, Ganjoo KN, Bartlett NL, Lemieux B, VanderWalde A, Herst J, Szer J, Bar MH, Cabanillas F, Dodds AJ, Montgomery PG, Pressnail B, Ellis T, Smith MR, Leonard JP
    Br J Haematol 2017 Jul;178(2):250-256
  • Safety and Tolerability of Idelalisib, Lenalidomide, and Rituximab in Relapsed and Refractory Lymphoma: The Alliance for Clinical Trials in Oncology A051201 and A051202 Phase 1 Trials
    Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, Richards KL, Cashen AF, Jaslowski A, Smith SE, Cheson BD, Hsi E, Leonard JP
    Lancet Haematol 2017 Apr;4(4):e176-e182
  • Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
    Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY
    Mol Ther 2017 Jan 4;25(1):285-295
  • Recurrent Somatic Mutations Affecting B-Cell Receptor Signaling Pathway Genes in Follicular Lymphoma
    Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, Fronick CC, Fulton RS, Kreisel F, Cashen AF, Carson KR, Berrien-Elliott MM, Bartlett NL, Griffith M, Griffith OL, Fehniger TA
    Blood 2017 Jan 26;129(4):473-483
  • Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations
    Diefenbach CS, Connors JM, Friedberg JW, Leonard JP, Kahl BS, Little RF, Baizer L, Evens AM, Hoppe RT, Kelly KM, Persky DO, Younes A, Kostakaglu L, Bartlett NL
    J Natl Cancer Inst 2016 Dec 31;109(4):djw249
  • Brentuximab Vedotin Activity in Diffuse Large B-Cell Lymphoma With CD30 Undetectable by Visual Assessment of Conventional Immunohistochemistry
    Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen ED
    Leuk Lymphoma 2017 Jul;58(7):1607-1616
  • Magnetic Resonance Image Guided Radiation Therapy for Primary Splenic Diffuse Large B-Cell Lymphoma: A Teaching Case
    Fischer-Valuck BW, Green O, Mazur T, Li H, Chundury A, Rao YJ, Bartlett NL, Mutic S, Huang J
    Pract Radiat Oncol 2017 Jan-Feb;7(1):e23-e26
  • Phase 1 Trial of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma: Alliance A051103
    Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, Smith SM, Czuczman M, Davids MS, Levine E, Lewis LD, Smith SE, Bartlett NL, Leonard JP, Cheson BD
    Blood 2016 Nov 24;128(21):2510-2516
  • Fine-Tuning the Treatment of Hodgkin's Lymphoma
    Bartlett NL
    N Engl J Med 2016 Jun 23;374(25):2490-2492
  • Clinical Characteristics and Outcomes of Patients With Hodgkin Lymphoma With Central Nervous System Involvement: An International Multicenter Collaboration
    Cheah CY, Brockelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MA
    Am J Hematol 2016 Sep;91(9):894-9
  • Patient-Reported Outcomes of Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large-Cell Lymphoma
    Chen R, Allibone S, Bartlett NL, Brice P, Chen A, Pose K, Rich L, Bonthapally V, Garfin PM, Fanale M
    Onco Targets Ther 2016 Apr 6;9:2027-34
  • US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816
    Press OW, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW
    J Clin Oncol 2016 Jun 10;34(17):2020-7
  • Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed by Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227
    Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, Bokstein F, Bovi JA, Solhjem MC, Mehta MP
    J Clin Oncol 2016 May 10;34(14):1620-5
  • A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Flinn IW, Bartlett NL, Blum KA, Ardeshna KM, LaCasce AS, Flowers CR, Shustov AR, Thress KS, Mitchell P, Zheng F, Skolnik JM, Friedberg JW
    Eur J Cancer 2016 Feb;54:11-7
  • Ibrutinib Combined With Bendamustine and Rituximab Compared With Placebo, Bendamustine, and Rituximab for Previously Treated Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma (HELIOS): A Randomised, Double-Blind, Phase 3 Study
    Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M
    HELIOS investigators

    Lancet Oncol 2016 Feb;17(2):200-11
  • A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
    Evens AM, Balasubramanian S, Vose JM, Harb W, Gordon LI, Langdon R, Sprague J, Sirisawad M, Mani C, Yue J, Luan Y, Horton S, Graef T, Bartlett NL
    Clin Cancer Res 2016 Mar 1;22(5):1059-66
  • The IL-15-Based ALT-803 Complex Enhances FcgammaRIIIa-Triggered NK Cell Responses and in Vivo Clearance of B Cell Lymphomas
    Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, Han K, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell BA, Keppel CR, Shah K, Hess B, Romee R, Piwnica-Worms DR, Cashen AF, Bartlett NL, Wong HC, Fehniger TA
    Clin Cancer Res 2016 Feb 1;22(3):596-608
  • Outcomes With R-CEOP for R-CHOP-Ineligible Patients With Diffuse Large B-Cell Lymphoma Are Highly Dependent on Cell of Origin Defined by Hans Criteria
    Rashidi A, Oak E, Carson KR, Wagner-Johnston ND, Kreisel F, Bartlett NL
    Leuk Lymphoma 2016 May;57(5):1191-1193
  • Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome
    Nguyen TT, Frater JL, Klein J, Chen L, Bartlett NL, Foyil KV, Kreisel FH
    Appl Immunohistochem Mol Morphol 2016 Jul;24(6):383-91
  • Ibrutinib as Initial Therapy for Patients With Chronic Lymphocytic Leukemia
    Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ
    RESONATE-2 Investigators

    N Engl J Med 2015 Dec 17;373(25):2425-2437
  • A Young Woman With Blurred Vision and Distal Paresthesias
    Kung NH, Bartlett NL, Yaseen NR, Van Stavern GP, Bucelli RC
    JAMA Neurol 2015 Dec 1;72(12):1519-1523
  • Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for Advanced Hodgkin Lymphoma in the Modern Era
    Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH
    Br J Haematol 2015 Nov;171(4):530-8
  • Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)
    Leonard JP, Jung SH, Johnson J, Pitcher BN, Bartlett NL, Blum KA, Czuczman M, Giguere JK, Cheson BD
    J Clin Oncol 2015 Nov 1;33(31):3635-40
  • Outcomes of Transformed Follicular Lymphoma in the Modern Era: A Report From the National LymphoCare Study (NLCS)
    Wagner-Johnston ND, Link BK, Byrtek M, Dawson KL, Hainsworth J, Flowers CR, Friedberg JW, Bartlett NL
    Blood 2015 Aug 13;126(7):851-7
  • Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108
    Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW
    J Clin Oncol 2015 Jul 20;33(21):2399-2404
  • Gray Zone Lymphoma With Features Intermediate Between Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: Characteristics, Outcomes, and Prognostication Among a Large Multicenter Cohort
    Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA
    Am J Hematol 2015 Sep;90(9):778-83
  • Maintenance Rituximab Every 2 Months Is More Toxic Than Every 3 Months in Patients With Non-Hodgkin Lymphoma
    Rashidi A, Oak E, Bartlett NL
    Blood 2015 May 21;125(21):3354-5
  • Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial
    Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ
    J Clin Oncol 2015 Jun 10;33(17):1936-42
  • Dacetuzumab Plus Rituximab, Ifosfamide, Carboplatin and Etoposide as Salvage Therapy for Patients With Diffuse Large B-Cell Lymphoma Relapsing After Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Trial
    Fayad L, Ansell SM, Advani R, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczkowski K, Belada D, Ng E, Drachman JG
    Leuk Lymphoma 2015 Sep;56(9):2569-78
  • Comparative Effectiveness of Anthracycline-Containing Chemotherapy in United States Veterans Age 80 and Older With Diffuse Large B-Cell Lymphoma
    Carson KR, Riedell P, Lynch R, Nabhan C, Wildes TM, Liu W, Ganti A, Roop R, Sanfilippo KM, O'Brian K, Liu J, Bartlett NL, Cashen A, Wagner-Johnston N, Fehniger TA, Colditz GA
    J Geriatr Oncol 2015 May;6(3):211-8
  • Brentuximab Vedotin Demonstrates Objective Responses in a Phase 2 Study of Relapsed/Refractory DLBCL With Variable CD30 Expression
    Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NL
    Blood 2015 Feb 26;125(9):1394-402
  • Extended Treatment With Brentuximab Vedotin in Patients With Relapsed or Refractory CD30-Positive Hematological Malignancies
    Forero-Torres A, Bartlett NL, Berryman RB, Chen R, Matous JV, Fanale MA, O'Connor OA, Olshefski R, Smith SE, Huebner D, Levine PL, Grove LE, Gopal AK
    Leuk Lymphoma 2015 Apr;56(4):1151-3
  • Therapy With Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Final Results of a Phase II Trial (CALGB 50501)
    Morrison VA, Jung SH, Johnson J, LaCasce A, Blum KA, Bartlett NL, Pitcher BN, Cheson BD
    Leuk Lymphoma 2015 Apr;56(4):958-64
  • Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30 + Peripheral T-Cell Lymphomas: Results of a Phase I Study
    Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR
    J Clin Oncol 2014 Oct 1;32(28):3137-43
  • A Phase II Study of Dacetuzumab (SGN-40) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) and Correlative Analyses of Patient-Specific Factors
    de Vos S, Forero-Torres A, Ansell SM, Kahl B, Cheson BD, Bartlett NL, Furman RR, Winter JN, Kaplan H, Timmerman J, Whiting NC, Drachman JG, Advani R
    J Hematol Oncol 2014 Jun 12;7(1):44
  • Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma
    Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Alizadeh AA, Denney DW Jr
    J Clin Oncol 2014 Jun 10;32(17):1797-803
  • Limited Utility of Routine Surveillance Imaging for Classical Hodgkin Lymphoma Patients in First Complete Remission
    Pingali SR, Jewell SW, Havlat L, Bast MA, Thompson JR, Eastwood DC, Bartlett NL, Armitage JO, Wagner-Johnston ND, Vose JM, Fenske TS
    Cancer 2014 Jul 15;120(14):2122-9
  • Objective Responses in Relapsed T-Cell Lymphomas With Single-Agent Brentuximab Vedotin
    Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y
    Blood 2014 May 15;123(20):3095-100
  • Retreatment With Brentuximab Vedotin in Patients With CD30-Positive Hematologic Malignancies
    Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A
    J Hematol Oncol 2014 Mar 19;7(1):24
  • Everolimus for Patients With Mantle Cell Lymphoma Refractory to or Intolerant of Bortezomib: Multicentre, Single-Arm, Phase 2 Study
    Wang M, Popplewell LL, Collins RH Jr, Winter JN, Goy A, Kaminski MS, Bartlett NL, Johnston PB, Lister J, Fanning SR, Tuscano JM, Beck JT, Kaya H, Robeva A, Fan J, Klimovsky J, Cheung W, Cherfi A, O'Connor OA
    Br J Haematol 2014 May;165(4):510-8
  • Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma
    Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y, Bartlett NL
    J Clin Oncol 2014 Mar 20;32(9):912-8
  • CD163 Immunohistochemistry Is Superior to CD68 in Predicting Outcome in Classical Hodgkin Lymphoma
    Klein JL, Nguyen TT, Bien-Willner GA, Chen L, Foyil KV, Bartlett NL, Duncavage EJ, Hassan A, Frater JL, Kreisel F
    Am J Clin Pathol 2014 Mar;141(3):381-7
  • Rituximab Is Associated With Improved Survival in Burkitt Lymphoma: A Retrospective Analysis From Two US Academic Medical Centers
    Wildes TM, Farrington L, Yeung C, Harrington AM, Foyil KV, Liu J, Kreisel F, Bartlett NL, Fenske TS
    Ther Adv Hematol 2014 Feb;5(1):3-12
  • High Incidence of Methotrexate Associated Renal Toxicity in Patients With Lymphoma: A Retrospective Analysis
    May J, Carson KR, Butler S, Liu W, Bartlett NL, Wagner-Johnston ND
    Leuk Lymphoma 2014 Jun;55(6):1345-9
  • Highlights in Lymphoma From the 2013 American Society of Hematology Annual Meeting and Exposition: Commentary
    Bartlett NL
    Clin Adv Hematol Oncol 2014 Feb;12 Suppl 6(2):18-23
  • The Role of Body Mass Index in Survival Outcome for Lymphoma Patients: US Intergroup Experience
    Hong F, Habermann TM, Gordon LI, Hochster H, Gascoyne RD, Morrison VA, Fisher RI, Bartlett NL, Stiff PJ, Cheson BD, Crump M, Horning SJ, Kahl BS
    Ann Oncol 2014 Mar;25(3):669-74
  • Brentuximab Vedotin in Patients Aged 60 Years or Older With Relapsed or Refractory CD30-Positive Lymphomas: A Retrospective Evaluation of Safety and Efficacy
    Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J, O'Meara MM, Fanale MA
    Leuk Lymphoma 2014 Oct;55(10):2328-34
  • Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis
    Evens AM, Advani R, Press OW, Lossos IS, Vose JM, Hernandez-Ilizaliturri FJ, Robinson BK, Otis S, Nadav Dagan L, Abdallah R, Kroll-Desrosiers A, Yarber JL, Sandoval J, Foyil K, Parker LM, Gordon LI, Blum KA, Flowers CR, Leonard JP, Habermann TM, Bartlett NL
    J Clin Oncol 2013 Nov 10;31(32):4132-9
  • Therapy in Primary Mediastinal B-Cell Lymphoma
    Cashen AF, Christian BA, Bartlett NL
    N Engl J Med 2013 Jul 18;369(3):282-3
  • Anaplastic Large-Cell Lymphoma With Aberrant Expression of Multiple Cytokeratins Masquerading as Metastatic Carcinoma of Unknown Primary
    Nguyen TT, Kreisel FH, Frater JL, Bartlett NL
    J Clin Oncol 2013 Nov 20;31(33):e443-5
  • Limited-Stage Hodgkin Lymphoma
    Bartlett NL
    Am Soc Clin Oncol Educ Book 2013;2013:374-80
  • Plasma Epstein-Barr Virus DNA Predicts Outcome in Advanced Hodgkin Lymphoma: Correlative Analysis From a Large North American Cooperative Group Trial
    Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh WS, Hong F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, Bartlett NL, Stiff P, Cheson BD, Advani R, Miller TP, Kahl BS, Horning SJ, Ambinder RF
    Blood 2013 May 2;121(18):3547-53
  • Assessment of Cellular Proliferation in Tumors by PET Using 18F-ISO-1
    Dehdashti F, Laforest R, Gao F, Shoghi KI, Aft RL, Nussenbaum B, Kreisel FH, Bartlett NL, Cashen A, Wagner-Johnston N, Mach RH
    J Nucl Med 2013 Mar;54(3):350-7
  • The Efficacy and Tolerability of Adriamycin, Bleomycin, Vinblastine, Dacarbazine and Stanford V in Older Hodgkin Lymphoma Patients: A Comprehensive Analysis From the North American Intergroup Trial E2496
    Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ
    Br J Haematol 2013 Apr;161(1):76-86
  • The Anti-CD80 Primatized Monoclonal Antibody, Galiximab, Is Well-Tolerated but Has Limited Activity in Relapsed Hodgkin Lymphoma: Cancer and Leukemia Group B 50602 (Alliance)
    Smith SM, Schoder H, Johnson JL, Jung SH, Bartlett NL, Cheson BD
    Leuk Lymphoma 2013 Jul;54(7):1405-10
  • Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)
    Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ
    J Clin Oncol 2013 Feb 20;31(6):684-91
  • Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma
    Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, Woolcock BW, Farinha P, Fisher RI, Rimsza LM, Bartlett NL, Cheson BD, Shepherd LE, Advani RH, Connors JM, Kahl BS, Gordon LI, Horning SJ, Steidl C, Gascoyne RD
    J Clin Oncol 2013 Feb 20;31(6):692-700
  • Pilot Study of Dacetuzumab in Combination With Rituximab and Gemcitabine for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, Northfelt DW, Whiting NC, Drachman JG, Lobuglio AF, Moskowitz CH
    Leuk Lymphoma 2013 Feb;54(2):277-83
  • Solid, Low-Attenuation Splenic Lesions on Computed Tomography in Patients With Indolent Lymphoma Often Signal Transformation: A Series of Ten Patients
    Welch JS, Foyil KV, Powers ML, Middleton WD, Bartlett NL
    Clin Lymphoma Myeloma Leuk 2012 Dec;12(6):452-4
  • Tumor-Associated Macrophages Predict Inferior Outcomes in Classic Hodgkin Lymphoma: A Correlative Study From the E2496 Intergroup Trial
    Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, Steidl C, Gordon LI, Horning SJ, Gascoyne RD
    Blood 2012 Oct 18;120(16):3280-7
  • Brentuximab Vedotin in Transplant-Naive Patients With Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies
    Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, Younes A
    Oncologist 2012;17(8):1073-80
  • Increased Body Mass Index Is Associated With Improved Survival in United States Veterans With Diffuse Large B-Cell Lymphoma
    Carson KR, Bartlett NL, McDonald JR, Luo S, Zeringue A, Liu J, Fu Q, Chang SH, Colditz GA
    J Clin Oncol 2012 Sep 10;30(26):3217-22
  • Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
    Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A
    J Clin Oncol 2012 Jun 20;30(18):2190-6
  • Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study
    Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA
    Clin Lymphoma Myeloma Leuk 2012 Aug;12(4):238-43
  • Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
    Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R
    J Clin Oncol 2012 Jun 20;30(18):2183-9
  • Progressive Multifocal Leukoencephalopathy in a Patient With Hodgkin Lymphoma Treated With Brentuximab Vedotin
    Wagner-Johnston ND, Bartlett NL, Cashen A, Berger JR
    Leuk Lymphoma 2012 Nov;53(11):2283-6
  • Interim [(18)F]Fluorodeoxyglucose Positron Emission Tomography Imaging in Stage I-II Non-Bulky Hodgkin Lymphoma: Would Using Combined Positron Emission Tomography and Computed Tomography Criteria Better Predict Response Than Each Test Alone?
    Kostakoglu L, Schoder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, Lacasce AS, Jung SH, Bartlett NL, Canellos GP, Cheson BD
    Leuk Lymphoma 2012 Nov;53(11):2143-2150
  • Identification of an Active, Well-Tolerated Dose of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
    Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M
    Blood 2012 May 3;119(18):4115-22
  • A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients With Relapsed/Refractory CD30-Positive Hematologic Malignancies
    Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL
    Clin Cancer Res 2012 Jan 1;18(1):248-255
  • A Phase II Study of the Survivin Suppressant YM155 in Patients With Refractory Diffuse Large B-Cell Lymphoma
    Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S
    Cancer 2012 Jun 15;118(12):3128-34
  • Extended Retreatment With Brentuximab Vedotin (SGN-35) Maintains Complete Remission in Patient With Recurrent Systemic Anaplastic Large-Cell Lymphoma
    Foyil KV, Kennedy DA, Grove LE, Bartlett NL, Cashen AF
    Leuk Lymphoma 2012 Mar;53(3):506-7
  • A Phase 2 Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
    Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL
    Blood 2011 Nov 10;118(19):5119-25
  • Composite Diffuse Large B-Cell Lymphoma and Precursor B Lymphoblastic Lymphoma Presenting as a Double-Hit Lymphoma With MYC and BCL2 Translocation
    Nanua S, Bartlett NL, Hassan A, Robirds D, Branson J, Frater JL, Nguyen TT, Kreisel F
    J Clin Pathol 2011 Nov;64(11):1032-4
  • Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated With Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation
    Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, Dipersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA
    Biol Blood Marrow Transplant 2011 Nov;17(11):1646-52
  • Doxorubicin, Vinblastine, and Gemcitabine (CALGB 50203) for Stage I/II Nonbulky Hodgkin Lymphoma: Pretreatment Prognostic Factors and Interim PET
    Straus DJ, Johnson JL, Lacasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schoder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD
    Blood 2011 May 19;117(20):5314-20
  • 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation
    Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL
    J Nucl Med 2011 Mar;52(3):386-92
  • A Phase III Study of Anti-B4-Blocked Ricin as Adjuvant Therapy Post-Autologous Bone Marrow Transplant: CALGB 9254
    Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, For The Cancer Leukemia Group B And Eastern Cooperative Oncology Group
    Leuk Lymphoma 2011 Apr;52(4):587-96
  • Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
    O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Jo Lechowicz M, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S
    J Clin Oncol 2011 Mar 20;29(9):1182-9
  • The Present: Optimizing Therapy - Too Much or Too Little?
    Bartlett NL
    Hematology Am Soc Hematol Educ Program 2010;2010:108-14
  • Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
    Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A
    N Engl J Med 2010 Nov 4;363(19):1812-21
  • Serious Pulmonary Toxicity in Patients With Hodgkin's Lymphoma With SGN-30, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin Is Associated With an Fc{gamma}RIIIa-158 V/F Polymorphism
    Blum KA, Jung SH, Johnson JL, Lin TS, Hsi ED, Lucas DM, Byrd JC, Cheson BD, Bartlett NL
    Ann Oncol 2010 Nov;21(11):2246-2254
  • Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma: Results From a Multicenter Study
    Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD
    Cancer 2010 Jan 1;116(1):106-114
  • Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909
    Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP
    J Clin Oncol 2009 Dec 20;27(36):6101-8
  • A Phase II Study of SGN-30 (Anti-CD30 MAb) in Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
    Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, Bosly A, Pinter-Brown L, Kennedy D, Sievers EL, Gopal AK
    Br J Haematol 2009 Jul;146(2):171-9
  • Protein Losing Enteropathy Associated With Follicular Lymphoma of the Small Bowel
    Cashen AF, Rubin DC, Bartlett NL
    Am J Clin Oncol 2009 Apr;32(2):222-3
  • Phase II Study of 9-Aminocamptothecin in Previously Treated Lymphomas: Results of Cancer and Leukemia Group B 9551
    Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA
    Cancer Chemother Pharmacol 2009 Apr;63(5):793-8
  • High Expression of Nucleoside Transporter Protein HENT1 in Reed-Sternberg Cells Is Associated With Treatment Failure in Relapsed/Refractory Hodgkin Lymphoma Patients Treated With Gemcitabine, Vinorelbine and Liposomal Doxorubicin - A CALGB 59804 Correlative Study
    Lai R, Bartlett NL, Mackey JR, Jung SH, Johnson JL, Cook JR, Jones D, Cass CE, Young JD, Said J, Cheson B, Hsi ED
    Leuk Lymphoma 2008 Jun;49(6):1202-5
  • Thalidomide Has Limited Single-Agent Activity in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas: A Phase II Trial of the Cancer and Leukemia Group B
    Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD
    Br J Haematol 2008 Feb;140(3):313-9
  • A Phase 1 Multidose Study of SGN-30 Immunotherapy in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
    Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP, Bernstein SH, Bociek RG, Lorenz JM, Hart BW, Barton J
    Blood 2008 Feb 15;111(4):1848-54
  • Single Agent Bortezomib in the Treatment of Relapsed and Refractory Hodgkin Lymphoma: Cancer and Leukemia Group B Protocol 50206
    Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL
    Leuk Lymphoma 2007 Jul;48(7):1313-9
  • Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin (GVD), a Salvage Regimen in Relapsed Hodgkin's Lymphoma: CALGB 59804
    Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP
    Ann Oncol 2007 Jun;18(6):1071-9
  • Sequential Doxorubicin and Topotecan in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results of CALGB 59906
    Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett NL, Cancer and Leukemia Group B
    Leuk Lymphoma 2006 Aug;47(8):1511-7
  • Therapies for Relapsed Hodgkin Lymphoma: Transplant and Non-Transplant Approaches Including Immunotherapy
    Bartlett NL
    Hematology Am Soc Hematol Educ Program 2005:245-51
  • Rituximab Therapy Is Effective for Posttransplant Lymphoproliferative Disorders After Solid Organ Transplantation
    Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA
    Cancer 2005 Oct 15;104(8):1661-7
  • Flavopiridol Administered as a 24-Hour Continuous Infusion in Chronic Lymphocytic Leukemia Lacks Clinical Activity
    Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR
    Leuk Res 2005 Nov;29(11):1253-7
  • Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild Thrombocytopenia
    Schilder R, Molina A, Bartlett N, Witzig T, Gordon L, Murray J, Spies S, Wang H, Wiseman G, White C
    Cancer Biother Radiopharm 2004 Aug;19(4):478-81
  • Yttrium 90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients With Previously Treated B-Cell Lymphoma
    Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, Vo K, Theuer C, Pohlman B, Bartlett N, Wiseman G, Darif M, White C
    Clin Lymphoma 2004 Sep;5(2):98-101
  • Barriers to Clinical Trial Participation by Older Women With Breast Cancer
    Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, Bartlett N, Fleming G, Cohen HJ
    J Clin Oncol 2003 Jun 15;21(12):2268-75
  • Radiation Dosimetry Results From a Phase II Trial of Ibritumomab Tiuxetan (Zevalin TM) Radioimmunotherapy for Patients With Non-Hodgkin's Lymphoma and Mild Thrombocytopenia
    Wiseman GA, Leigh BR, Erwin WD, Sparks RB, Podoloff DA, Schilder RJ, Bartlett NL, Spies SM, Grillo-Lopez AJ, Witzig TE, White CA
    Cancer Biother Radiopharm 2003 Apr;18(2):165-78
  • Interdigitating Dendritic Reticulum Cell Tumor of Lymph Nodes: Case Report With Differential Diagnostic Considerations
    Ylagan LR, Bartlett NL, Kraus M
    Diagn Cytopathol 2003 May;28(5):278-81
  • Rituximab in Lymphocyte-Predominant Hodgkin Disease: Results of a Phase 2 Trial
    Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, Natkunam Y, Bartlett NL, Horning SJ
    Blood 2003 Jun 1;101(11):4285-9
  • Phase I Study of Pegylated Liposomal Doxorubicin and Gemcitabine in Patients With Advanced Malignancies
    Fracasso PM, Blum KA, Tan BR, Fears CL, Bartlett NL, Arquette MA, Clark RS
    Cancer 2002 Nov 15;95(10):2223-9
  • Survey of Oncologists' Perceptions of Barriers to Accrual of Older Patients With Breast Carcinoma to Clinical Trials
    Kornblith AB, Kemeny M, Peterson BL, Wheeler J, Crawford J, Bartlett N, Fleming G, Graziano S, Muss H, Cohen HJ
    Cancer 2002 Sep 1;95(5):989-96
  • Ibritumomab Tiuxetan Radioimmunotherapy for Patients With Relapsed or Refractory Non-Hodgkin Lymphoma and Mild Thrombocytopenia: A Phase II Multicenter Trial
    Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA
    Blood 2002 Jun 15;99(12):4336-42
  • Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma
    Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA
    J Clin Oncol 2002 May 15;20(10):2453-63
  • Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial
    Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA
    J Clin Oncol 2002 Feb 1;20(3):630-7
  • Dose-Escalated Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Etoposide (CHOPE) Chemotherapy for Patients With Diffuse Lymphoma: Cancer and Leukemia Group B Studies 8852 and 8854
    Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Canellos GP, Robert M, Johnson JL, Peterson BA
    Cancer 2001 Jul 15;92(2):207-17
  • Biodistribution and Dosimetry Results From a Phase III Prospectively Randomized Controlled Trial of Zevalin Radioimmunotherapy for Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma
    Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR
    Crit Rev Oncol Hematol 2001 Jul-Aug;39(1-2):181-94
  • Cyclin D1 as an Aid in the Diagnosis of Mantle Cell Lymphoma in Skin Biopsies: A Case Report
    Moody BR, Bartlett NL, George DW, Price CR, Breer WA, Rothschild Y, Kraus MD
    Am J Dermatopathol 2001 Oct;23(5):470-6
  • Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492
    Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, Cassileth P
    J Clin Oncol 2000 Mar;18(5):972-80
  • Primary Gastric Plasmacytoma: A Rare Cause of Hypertrophic Gastritis in an Adolescent
    Goyal A, Langer JC, Zutter M, Swanson P, Kraus MD, Bartlett N, Shackelford GD, Longtine JA, Perlmutter DH
    J Pediatr Gastroenterol Nutr 1999 Oct;29(4):424-30
  • Intravascular Lymphoma Associated With Endocrine Dysfunction: A Report of Four Cases and a Review of the Literature
    Kraus MD, Jones D, Bartlett NL
    Am J Med 1999 Aug;107(2):169-76
  • Splenic Pathology in Myelodysplasia: A Report of 13 Cases With Clinical Correlation
    Kraus MD, Bartlett NL, Fleming MD, Dorfman DM
    Am J Surg Pathol 1998 Oct;22(10):1255-66
  • Bone Marrow Staging in Patients With Non-Hodgkin's Lymphoma: Is Flow Cytometry a Useful Test? [See Comments]
    Naughton MJ, Hess JL, Zutter MM, Bartlett NL
    Cancer 1998 Mar 15;82(6):1154-9
  • Assessment of Knowledge About Cancer Pain Management by Physicians in Training
    Mortimer JE, Bartlett NL
    J Pain Symptom Manage 1997 Jul;14(1):21-8
  • Brief Chemotherapy, Stanford V, and Adjuvant Radiotherapy for Bulky or Advanced-Stage Hodgkin's Disease: A Preliminary Report
    Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ
    J Clin Oncol 1995 May;13(5):1080-8
  • Follicular Large-Cell Lymphoma: Intermediate or Low Grade?
    Bartlett NL, Rizeq M, Dorfman RF, Halpern J, Horning SJ
    J Clin Oncol 1994 Jul;12(7):1349-57
  • Phase I Trial of Doxorubicin With Cyclosporine as a Modulator of Multidrug Resistance
    Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI
    J Clin Oncol 1994 Apr;12(4):835-42
  • MACOP-B +/- Radiation Therapy for Diffuse Large Cell Lymphoma. Analysis of the Stanford Results According to Prognostic Indices
    Bartlett NL, Kwak LW, Horning SJ
    Cancer 1993 Jun 15;71(12):4034-42
  • Prognostic Factors in Inflammatory Breast Cancer. Univariate and Multivariate Analysis
    Fields JN, Kuske RR, Perez CA, Fineberg BB, Bartlett N
    Cancer 1989 Mar 15;63(6):1225-32
  • Inflammatory Carcinoma of the Breast: Treatment Results on 107 Patients
    Fields JN, Perez CA, Kuske RR, Fineberg BB, Bartlett N
    Int J Radiat Oncol Biol Phys 1989 Aug;17(2):249-55

Invited Publications

  • Hodgkin Lymphoma
    Triska G, Bartlett NL
    In: Abeloff’s Clinical Oncology 6th Edition (Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, Eds.). Elsevier; 1911-1925.e3, 2020
  • NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
    Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H
    J Natl Compr Canc Netw 2019 Jun 1;17(6):650-661
  • SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma
    Watkins MP, Fanale MA, Bartlett NL
    Clin Lymphoma Myeloma Leuk 2018 Feb;18(2):81-90
  • CD19-Targeted Immunotherapies for Treatment of Patients With Non-Hodgkin B-Cell Lymphomas
    Watkins MP, Bartlett NL
    Expert Opin Investig Drugs 2018 Jul;27(7):601-611
  • NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017
    Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H
    J Natl Compr Canc Netw 2017 Mar;15(3):293-311
  • NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016
    Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P
    J Natl Compr Canc Netw 2016 Sep;14(9):1067-79
  • Diffuse Large B-Cell Lymphoma Version 1.2016
    Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H
    J Natl Compr Canc Netw 2016 Feb;14(2):196-231
  • Radiation for Early-Stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Double-Edged Sword?
    Rashidi A, Bartlett NL
    Leuk Lymphoma 2016 Feb;57(2):249-251
  • A Safety Evaluation of Brentuximab Vedotin for the Treatment of Hodgkin Lymphoma
    Oak E, Bartlett NL
    Expert Opin Drug Saf 2016 Jun;15(6):875-82
  • Blinatumomab for the Treatment of B-Cell Lymphoma
    Oak E, Bartlett NL
    Expert Opin Investig Drugs 2015 May;24(5):715-24
  • Biologic Agents in the Management of Hodgkin Lymphoma
    Rashidi A, Bartlett NL
    J Natl Compr Canc Netw 2015 May;13(5):587-96
  • Lymphomas of the Head and Neck
    Wang T, Bartlett NL
    In: Cummings Otolaryngology: Head and Neck Surgery. Canada: Elsevier Saunders; 2015; 1805-1815
  • Management of Classical Hodgkin Lymphoma
    Sanfilippo K, Bartlett NL
    In: Abutalib SA, Markman M. Cancer Consult. Hoboken, NJ: Wiley Blackwell; 2014: 229-234
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015
    Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wilson L, Yahalom J, Zafar N, Dwyer M, Sundar H
    National comprehension cancer network

    J Natl Compr Canc Netw 2015 Mar;13(3):326-62
  • Highlights in Lymphoma From the 2013 American Society of Hematology Annual Meeting and Exposition
    Bartlett NL
    Clin Adv Hematol Oncol 2014 Feb;12(2 Suppl 6):18-23
  • Non-Hodgkin's Lymphomas, Version 4.2014
    Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H
    National comprehensive cancer network

    J Natl Compr Canc Netw 2014 Sep;12(9):1282-303
  • Non-Hodgkin's Lymphomas, Version 2.2014
    Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H
    J Natl Compr Canc Netw 2014 Jun;12(6):916-46
  • Non-Hodgkin's Lymphomas, Version 1.2013
    Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M
    National comprehensive cancer network

    J Natl Compr Canc Netw 2013 Mar 1;11(3):257-72; quiz 273
  • Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma-"Do No Harm"
    Bartlett NL
    Clin Adv Hematol Oncol 2013 Jun;11(6):385-7
  • Lymphoma Surveillance Counterpoint: USA
    Carson KR, Bartlett NL
    In: Johnson FE, Maehara Y, Browman GP, Margenthaler JA, Audisio RA, Thompson JF, Johnson DY, Earle CC, Virgo KS, eds. Patient Surveillance After Cancer Treatment. New York, NY: Humana Press; 2013; 461-466
  • Non-Hodgkin's Lymphomas, Version 3.2012
    Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA
    J Natl Compr Canc Netw 2012 Dec 1;10(12):1487-98
  • Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma
    Foyil KV, Bartlett NL
    Cancer J 2012 Sep-Oct;18(5):450-6
  • Where Does Brentuximab Vedotin Fit Into the Management of Patients With Hodgkin Lymphoma?
    Goyal SD, Bartlett NL
    Curr Hematol Malig Rep 2012 Sep;7(3):179-85
  • Advances in LLM: Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
    Bartlett NL
    Clin Adv Hematol Oncol 2012 Jul;10(7):468-71
  • Role of Routine Imaging in Lymphoma
    Wagner-Johnston ND, Bartlett NL
    J Natl Compr Canc Netw 2011 May;9(5):575-84; quiz 585
  • Non-Hodgkin's Lymphomas
    Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N
    J Natl Compr Canc Netw 2011 May;9(5):484-560
  • Brentuximab Vedotin for the Treatment of CD30+ Lymphomas
    Foyil KV, Bartlett NL
    Immunotherapy 2011 Apr;3(4):475-85
  • Anti-CD30 Antibodies for Hodgkin Lymphoma
    Foyil KV, Bartlett NL
    Curr Hematol Malig Rep 2010 Jul;5(3):140-7
  • Something Old, Something New: Options for Treating Relapsed Mantle Cell Lymphoma
    Wagner-Johnston ND, Bartlett NL
    Oncology (Williston Park) 2009 Jul;23(8):694, 702-3
  • Drug Development for Recurrent and Refractory Classical Hodgkin Lymphoma
    Wildes TM, Bartlett NL
    Leuk Lymphoma 2009 Apr;50(4):529-40
  • Salvage Regimens for Hodgkin Lymphoma
    Cashen AF, Bartlett NL
    Clin Adv Hematol Oncol 2008 Jul;6(7):517-24
  • Modern Treatment of Hodgkin Lymphoma
    Bartlett NL
    Curr Opin Hematol 2008 Jul;15(4):408-14
  • Tumors and Masses: Lymphoma
    Bartlett NL, Fenske T
    In: Pearson et al (eds), Thoracic Surgery, 3rd ed, WB Saunders Company 2007: 1622-1633
  • Lymphoma
    Bartlett NL, Wagner-Johnston N
    In: Govindan R (ed), The Washington Manual of Oncology, 2nd ed, Lippincott Williams & Wilkins, 2007: 286-303
  • Therapy of Relapsed Hodgkin Lymphoma
    Cashen AF, Bartlett NL
    Blood Rev 2007 Sep;21(5):233-43
  • Management of Advanced Hodgkin's Lymphoma: "Not One Size Fits All"
    Bartlett NL
    In: Perry MC, Govindan R (eds) American Society of Clinical Oncology Educational Book 2006
  • Management of Advanced Stage Hodgkin's Lymphoma
    Bartlett NL, Smukler AJ
    Cancer Treat Res 2006;131:333-52
  • 90Yttrium-Ibritumomab Tiuxetan: A Novel Treatment for Non-Hodgkin's Lymphoma
    Blum KA, Bartlett NL
    Expert Opin Biol Ther 2004 Aug;4(8):1323-31
  • New Therapies in Hodgkin's Lymphoma
    Bartlett N
    Clin Adv Hematol Oncol 2004 Feb;2(2):80, 83
  • Escalated BEACOPP: Two Steps Forward, One Step Back
    Bartlett NL
    American Journal of Oncology Review 2004;2:119-123
  • Hodgkin's Disease: Chemotherapy
    Blum KA, Bartlett NL
    In: Rakel R, Bope E, (eds) Conn's Current Therapy, WB Saunders Company, 2004
  • Targeting CD30 in Patients With Hodgkin's Lymphoma
    Blum KA, Bartlett NL
    Biological Therapy of Lymphoma 2003;6:11-14
  • Antibodies for the Treatment of Diffuse Large Cell Lymphoma
    Blum KA, Bartlett NL
    Semin Oncol 2003 Aug;30(4):448-56
  • Hodgkin's Disease Module
    Bartlett NL
    PIER-ACP, 2003
  • Extranodal Marginal Zone (MALT) Lymphoma
    Blum KA, Bartlett NL
    Contemporary Oncology 2002;1:1-8
  • Lymphoma
    Wagner ND, Bartlett NL
    In: Govindan R, Arquette M (eds) The Washington Manual of Oncology, Lippincott Williams & Wilkins, 2002
  • Tumors and Masses: Lymphoma
    Bartlett NL, Wagner ND
    In: Pearson et al (eds) Thoracic Surgery, 2nd ed, WB Saunders Company, 2002
  • Macroglobulinemia
    Bartlett NL, Arackal SM
    In: Austen FK, Frank MM, Atkinson JP, Cantor H (eds) Samter's Immunologic Diseases, 6th ed, Lippincott Williams & Wilkins, 2001
  • Low Grade Lymphoma
    Bartlett NL, Horning SJ
    In: Haskell CM (ed) Cancer Treatment, 5th ed, Philadelphia, WB Saunders Company, 2001
  • Treatment Advances in Non-Hodgkin's Lymphoma
    Tan BR, Bartlett NL
    Expert Opin Pharmacother 2000 Mar;1(3):451-66
  • Hodgkin's Disease: Prognostic Factors and Short-Course Regimens
    Bartlett NL, Arackal SM
    Curr Oncol Rep 2000 Mar;2(2):163-71
  • Non-Hodgkin's Lymphomas
    Bartlett NL, Wagner ND
    Cancer Chemother Biol Response Modif 1999;18:293-323
  • T-Small Lymphocyte Disorders
    Bartlett NL, Longo DL
    Semin Hematol 1999 Apr;36(2):164-70
  • Hodgkin's Disease
    Bartlett NL, Horning SJ
    In: Foley JF, Vose JM, Armitage JO (eds) Current Therapy in Cancer, 2nd ed, Philadelphia, WB Saunders Company, 1998
  • Treatment of Aggressive Histology Lymphoma
    Bartlett NL
    Curr Opin Oncol 1997 Sep;9(5):413-9
  • Combined Modality Therapy
    Bartlett NL, Wasserman TH
    In: Perry MC (ed) Chemotherapy Source Book, 2nd ed, Baltimore, Williams & Wilkens, 109-126; 1996
  • Low Grade Lymphoma
    Bartlett NL, Horning SJ
    In: Haskell CM (ed) Cancer Treatment, 4th ed, Philadelphia, WB Saunders Company, 1006-1013; 1995
  • Hodgkin's Disease
    Bartlett NL, Horning SJ
    In: Foley JF, Vose JM, Armitage JO (eds) Current Therapy in Cancer, 1st ed, Philadelphia, WB Saunders Company, 241-50; 1994
  • Composite and Discordant Lymphomas
    Bartlett NL, Horning SJ
    In: Foley JF, Vose JM, Armitage JO (eds) Current Therapy in Cancer, 1st ed, Philadelphia, WB Saunders Company, 290-94; 1994
  • The Modulation of Multidrug Resistance: Clinical Studies at Stanford
    Fisher GA, Brophy NA, Yahanda AM, Adler KM, Lum BL, Bartlett NL, Halsey J, Sikic BI
    In:  Miyazaki T, Takaku F, Sakurada K (eds) The Mechanism and New Approach on Drug-Resistance of Cancer Cells Proceedings of the International Symposium, Sapporo, Japan: 255-66; 1993
  • Serum Markers in Germ Cell Neoplasms
    Bartlett NL, Freiha FS, Torti FM
    Hematol Oncol Clin North Am 1991 Dec;5(6):1245-60